Get the Stockscreener App
34.18
0.90%
-0.31
After Hours:
34.18
Arrivent Biopharma Inc stock is traded at $34.18, with a volume of 401.74K.
It is down -0.90% in the last 24 hours and up +12.62% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
See More
Previous Close:
$34.49
Open:
$34.69
24h Volume:
401.74K
Relative Volume:
0.73
Market Cap:
$1.59B
Revenue:
-
Net Income/Loss:
$-166.31M
P/E Ratio:
-7.6633
EPS:
-4.4602
Net Cash Flow:
$-160.59M
1W Performance:
-1.61%
1M Performance:
+12.62%
6M Performance:
+74.03%
1Y Performance:
+69.46%
1-Day Range:
$34.05
$35.15
1-Week Range:
$33.99
$35.60
52-Week Range:
$16.10
$35.83
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
34.18 | 1.61B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Dec-10-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
ArriVent’s Emerging CDH17-Targeted ADC Pipeline Supports Maintained Buy Rating and $45 Price Target - TipRanks
ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings - TradingView
Price-Driven Insight from (AVBP) for Rule-Based Strategy - Stock Traders Daily
Number of shareholders of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Number of shareholders of ArriVent BioPharma, Inc. – BOATS:AVBP - TradingView
Price to book forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Enterprise value to revenue forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Price to book forward of ArriVent BioPharma, Inc. – BOATS:AVBP - TradingView
Price to earnings forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Price to earnings forward of ArriVent BioPharma, Inc. – BOATS:AVBP - TradingView
Price to sales forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
AVBP 260717 5.00P (AVBP260717P5000) Stock Options Chain | Quotes & News - Moomoo
ArriVent BioPharma, Inc. Actuals & Estimates (NASDAQ:AVBP) - TradingView
AVBP Forecast — Price Target — Prediction for 2027 - TradingView
Arrivent Biopharma Inc (AVBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 4 Arrivent Biopharma Inc For: 22 June By Investing.com - Investing.com India
ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options - Stock Titan
ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options at $31.74 - Stock Titan
ArriVent BioPharma Stockholders Back Board and Auditor Slate - TipRanks
ArriVent BioPharma (NASDAQ: AVBP) 2026 meeting backs board, auditor - Stock Titan
Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD - Investing.com UK
Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD By Investing.com - Investing.com South Africa
Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $31.74 - Moomoo
(AVBP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arrivent Biopharma Inc (AVBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arrivent Biopharma Inc (AVBP) Institutional Confidence - TradingKey
Arrivent Biopharma Inc (AVBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arrivent Biopharma Inc (AVBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arrivent Biopharma Inc (AVBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AVBP: Directors were elected through 2029 and the auditor's appointment was ratified with strong support - TradingView
Arrivent Biopharma Inc (AVBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arrivent Biopharma Inc (AVBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arrivent Biopharma Inc (AVBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ArriVent BioPharma (AVBP) Stock Valuation After Growing Expectations For EGFR Firmonertinib Trials - Sahm
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
AVBP Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D InvestmentsTangible Book Value - newsline.com
AVBP Q1 2026 Earnings: EPS Miss Slightly Wider Than Forecast as Pre-Revenue Biotech Advances PipelineFinancial Data - dars.gov.et
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
(AVBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
AVBP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Vanda (VNDA), ArriVent BioPharma, Inc. (AVBP) and Medtronic (MDT) - The Globe and Mail
ArriVent’s MRG007 Phase I Trial Progress Adds Long-Term Option Value for AVBP Investors - TipRanks
Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight on ArriVent BioPharma stock By Investing.com - Investing.com Canada
Why Is ArriVent BioPharma, Inc. Common Stock (AVBP) Stock Down Today? - Meyka
Analyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data - TipRanks
Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $50 - Moomoo
AVBP Q1 2026 Earnings: EPS Misses Estimates as Stock Surges 11% on Pipeline OptimismShare Dilution Risk - The Legal Advocate
ArriVent BioPharma Price Target Raised to $45.00/Share From $43.00 by Truist Securities - Moomoo
ArriVent Biopharma assumed with a Buy at Truist - TipRanks
Truist Financial Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $45 - Moomoo
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arrivent Biopharma Inc Stock (AVBP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin | Chief Operating Officer |
Jul 11 '25 |
Option Exercise |
2.28 |
11,153 |
25,429 |
135,736 |
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):